Position of the Transparency Council – Verzenios (abemaciclib)
At its meeting on 20 January 2025, the Transparency Council adopted position No. 8/2025 on the evaluation of the drug Verzenios (abemaciclib) under the drug program: “Treatment of patients with breast cancer (ICD-10: C50)”.